Position in NVS
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$600,551
+$295,815 QoQ
Shares Held
3,832
+92.1% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.18%
of 13F equity value
Holder Rank
#811
of 1,603 holders
Holding Since
Dec 2020
11 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Interchange Capital Partners, LLC holds $15,658,756 across 10 Drug Manufacturers - General names. NVS ranks #8 (3.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
16,195 | $4,075,309 | |
| 2 | JNJ |
Johnson & Johnson
|
13,368 | $3,395,070 | |
| 3 | LLY |
ELI LILLY & Co
|
2,290 | $2,746,694 | |
| 4 | MRK |
Merck & Co., Inc.
|
16,005 | $2,056,642 | |
| 5 | AMGN |
Amgen Inc
|
2,111 | $764,435 | |
| 6 | MDCX |
Medicus Pharma Ltd.
|
1,586,871 | $707,744 | |
| 7 | GILD |
Gilead Sciences, Inc.
|
5,395 | $681,604 | |
| 8 | NVS |
Novartis AG
This page
|
3,832 | $600,551 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $600,551 | 3,832 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $304,736 | 1,995 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $544,586 | 3,950 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $519,884 | 4,054 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $426,076 | 3,521 | Shares | Sole | 2025-07-31 | |
| 2025-03-31 | $220,618 | 1,979 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $201,820 | 2,074 | Shares | Sole | 2025-02-11 | |
| 2024-09-30 | $249,248 | 2,167 | Shares | Sole | 2024-10-28 | |
| 2024-06-30 | $230,911 | 2,169 | Shares | Sole | 2024-07-31 | |
| 2023-03-31 | $208,656 | 2,268 | Shares | Sole | 2023-05-15 | |
| 2020-12-31 | $126,725 | 1,342 | Shares | Sole | 2021-02-16 | |
| No filing history on record for this holder in this stock. | ||||||